In June 2009, Centocor’s (now COBI) lawsuit alleging that Abbott’s HUMIRA® anti-TNF alpha product infringes Centocor’s ’775 patent went to trial in Federal District Court in the Eastern Dis- trict of Texas. On June 28, 2009 a jury returned a verdict finding the patent valid and willfully infringed, and awarded Centocor damages of approximately $1.7 billion. A bench trial on Abbott’s defenses, of inequitable conduct and prosecution laches, was held in August 2009, and the District Court decided these issues in favor of Cento- cor. All of Abbott’s post trial motions have been denied except that the District Court granted Abbott’s motion to overturn the jury finding of willfulness. Judgment in the amount of approximately $1.9 billion, inclusive of interest was entered in favor of Centocor in December 2009, and Abbott filed an appeal to the Court of Appeals for the Federal Circuit; therefore the Company has not reflected any of the $1.9 billion in its consolidated financial statements. The oral argument on appeal was held on November 2, 2010. In December 2009, Centocor also filed a new lawsuit in the Eastern District of Texas seeking damages for infringement of the ’775 patent attribut- able to sales of HUMIRA® subsequent to the jury verdict in June 2009. On February 23, 2011, the Court of Appeals reversed the June 2009 decision and the $1.9 billion judgement of the District Court. The following chart summarizes various patent lawsuits concerning products of the Company’s subsidiaries that have yet to proceed to trial: non-infringement, invalidity and unenforceability of these patents. In the event the subsidiary of the Company involved is not success- ful in these actions, or the statutory 30-month stay expires before a ruling from the District Court is obtained, the firms involved will have the ability, upon FDA approval, to introduce generic versions of the product at issue resulting in very substantial market share and revenue losses for the product of the Company’s subsidiary. The following chart indicates lawsuits pending against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of As noted in the following chart, 30-month stays expired during 2009, 2010, and will expire in 2011, 2012 and 2013 with respect to ANDA challenges regarding various products: JOHNSON & JOHNSON 2010 ANNUAL REPORT 66 * Trial date to be scheduled. ** Q reflects the Company’s fiscal quarter. Brand Name Patent/NDA Generic Trial Date 30-Month Product Holder Challenger Court Date** Filed Stay Expiration CONCERTA® Ortho-McNeil-Janssen Andrx D. DE Q 4 / 07 09 / 05 None 18, 27, 36 and 54 mg controlled ALZA KUDCO D. DE * 01 10 05 / 12 release tablet Impax and Teva D. DE * 11 / 10 04 13 LEVAQUIN® 250, 500, 750 mg tablet Ortho-McNeil Lupin D. NJ * 10 / 06 03 / 09 ORTHO TRI-CYCLEN® LO Ortho-McNeil Watson D. NJ * 10 / 08 03 / 11 0.18 mg/0.025 mg, 0.215 mg/0.025 mg Sandoz D. NJ * 10 11 and 0.25 mg/0.025 mg Lupin D. NJ * 01 / 10 06 / 12 Mylan D. NJ * 11 10 04 13 ULTRAM ER® 100, 200, 300 mg tablet Ortho-McNeil/Biovail Par D. DE Q 2 / 09 05 / 07 09 / 09 06 07 11 09 10 / 07 03 / 10 ULTRAM ER® 100, 200, 300 mg tablet Ortho-McNeil/Biovail Impax D. DE 08 / 08 01 / 11 11 08 03 11 ULTRAM ER® 100, 200, 300 mg tablet Ortho-McNeil/Biovail Paddock D. MN * 09 / 09 01 / 12 ULTRAM ER® 100, 200, 300 mg tablet Ortho-McNeil/Biovail Cipher D. DE * 10 / 09 03 / 12 ULTRAM ER® 100, 200, 300 mg tablet Ortho-McNeil/Biovail Lupin D. DE * 01 / 10 06 / 12 PREZISTA® Tibotec Mylan D. NJ * 11 / 10 12 / 13 Tibotec Lupin D. NJ * 11 10 12 13 J&J Plaintiff/ Product Company Patents Patent Holder Court Trial Date** Date Filed CYPHER® Stent Cordis Wall Wall E.D. TX Q 2 / 11 11 / 07 CYPHER® Stent Cordis Saffran Saffran E.D. TX *Trial concluded 10 / 07 Blood Glucose Meters and Strips LifeScan Wilsey Roche Diagnostics D. DE * 11 / 07 SIMPONI® Centocor/COBI Salfeld Abbott Laboratories MA * 05 / 09 SIMPONI® Centocor/COBI Boyle Bayer Healthcare MA *** 08 / 09 STELARA® Centocor/COBI Salfeld Abbott GmbH MA * 08 / 09 * Trial date to be scheduled. ** Q reflects the Company’s fiscal quarter. *** Summary judgment granted. LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)